CD39, also known as ENTPD1 (ectonucleoside triphosphate diphosphohydrolase­1) and NTPDase-1, is a two pass, type II transmembrane protein with an extracellular active site that hydrolyzes extracellular ATP and ADP to AMP. CD39 can hydrolyze ATP and ADP equally well. CD39 was originally discovered as a B lymphocyte cell surface marker, but it is also expressed on the surface of natural killer (NK) cells, T cells, neuron tissues and some endothelial cells. CD39 is involved in the processes of thromboregulation and vascular inflammation. In the central nervous system, CD39 hydrolyzes extracellular ATP and other nucleotides to regulate purinergic signaling and transmission. It is also implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. The mutations in the CD39 gene cause SPG64 (spastic paraplegia 64), an autosomal recessive neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. The administration of soluble ecto-enzyme of ENTPD1 may have therapeutic potential for treating some vascular and transplantation­associated diseases. Inhibition of this protein's activity may confer anticancer benefits.

CD39, also known as ENTPD1 (ectonucleoside triphosphate diphosphohydrolase­1) and NTPDase-1, is a two pass, type II transmembrane protein with an extracellular active site that hydrolyzes extracellular ATP and ADP to AMP. CD39 can hydrolyze ATP and ADP equally well. CD39 was originally discovered as a B lymphocyte cell surface marker, but it is also expressed on the surface of natural killer (NK) cells, T cells, neuron tissues and some endothelial cells. CD39 is involved in the processes of thromboregulation and vascular inflammation. In the central nervous system, CD39 hydrolyzes extracellular ATP and other nucleotides to regulate purinergic signaling and transmission. It is also implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. The mutations in the CD39 gene cause SPG64 (spastic paraplegia 64), an autosomal recessive neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. The administration of soluble ecto-enzyme of ENTPD1 may have therapeutic potential for treating some vascular and transplantation­associated diseases. Inhibition of this protein's activity may confer anticancer benefits.

 

Product Details

 

Gene Symbol: CD39; ENTPD1; SPG64; ATPDase; NTPDase-1; Ecto-ATPase 1; Ecto-ATPDase 1

 

NCBI Gene ID: 953

 

Uniprot Entry: P49961

 

Construct Details: The recombinant human CD39 ECD protein is expressed as a 452 amino acid protein consisting of Thr38- Val478 region of CD39 and a N-terminal His-tag. It contains 6 potential sites for N-linked glycosylation

 

Source: Human cells stably expressing human CD39 ECD and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

MAHHHHHHHH STQNKALPEN VKYGIVLDAG SSHTSLYIYK WPAEKENDTG VVHQVEECRV 

        70         80         90        100        110        120 

KGPGISKFVQ KVNEIGIYLT DCMERAREVI PRSQHQETPV YLGATAGMRL LRMESEELAD 

       130        140        150        160        170        180 

RVLDVVERSL SNYPFDFQGA RIITGQEEGA YGWITINYLL GKFSQKTRWF SIVPYETNNQ 

       190        200        210        220        230        240 

ETFGALDLGG ASTQVTFVPQ NQTIESPDNA LQFRLYGKDY NVYTHSFLCY GKDQALWQKL 

       250        260        270        280        290        300 

AKDIQVASNE ILRDPCFHPG YKKVVNVSDL YKTPCTKRFE MTLPFQQFEI QGIGNYQQCH 

       310        320        330        340        350        360 

QSILELFNTS YCPYSQCAFN GIFLPPLQGD FGAFSAFYFV MKFLNLTSEK VSQEKVTEMM 

       370        380        390        400        410        420 

KKFCAQPWEE IKTSYAGVKE KYLSEYCFSG TYILSLLLQG YHFTADSWEH IHFIGKIQGS 

       430        440        450 

DAGWTLGYML NLTNMIPAEQ PLSTPLSHST YV 

  

M.W.: Calculated molecular mass (kDa): 51.7; Estimated by SDS-PAGE under reducing condition (kDa): 65-70

 

Calculated PI: 6.14

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 77865

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above)

 

Formulation: Supplied at 0.25 mg/ml in sterile PBSpH7.4 (carrier & preservative free). 

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Hydrolyzes the 5’-phosphate groups from the enzymatic substrate adenosine-5’-triphosphate (ATP)

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

1. Int. J. Cancer 29:373 (1982).

2. J. Immunol. 146:2235 (1991).

3. J. Biol. Chem. 271:33116 (1996)

4. Semin. Thromb. Hemost. 31:234 (2005)

5. Science 343:506 (2014)

 

 

 

Additional supporting documents, including PDS, COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.